OKUR earnings analysis
What we found in OKUR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
OnKure remained a clinical-stage, pre-revenue biotechnology company in Q2 2026, reporting a $15.346 million net loss versus $15.390 million a year earlier. Operating cash burn improved in the first half, while the March private placement increased cash, cash equivalents and marketable securities to $176.4 million and supports the stated runway into 2029. The central value drivers remain execution toward first-half 2027 IND submissions for OKI-345 and OKI-355, against continued losses, expected higher 2026 operating spending, and material development risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Quarterly loss was essentially flat year over year
- The Q2 2026 net loss was $15.346 million, modestly narrower than the $15.390 million loss in Q2 2025. The company reported no product revenue and does not expect commercial product revenue for the foreseeable future.
- R&D held flat while clinical costs increased
- R&D expense was flat at $12.611 million in Q2 2026 versus $12.613 million a year earlier; a $0.5 million increase in clinical-trial costs was offset by a $0.5 million reduction in outsourced preclinical R&D.
- Operating cash burn improved by $3.987 million
- Operating cash use improved to $23.292 million for the first six months of 2026 from $27.279 million in the prior-year period. The filing does not separately disclose current-period capital expenditures, so free cash flow and capex intensity cannot be calculated reliably.
- March financing materially strengthened liquidity
- Cash, cash equivalents and marketable securities totaled $176.4 million at June 30, 2026, following approximately $150.0 million of gross proceeds from the March 2026 private placement. Management believes resources fund planned operations into 2029.
- Pipeline has defined 2027 IND milestones
- The two lead next-generation PI3Kα programs, OKI-345 and OKI-355, are targeted for IND submissions in the first half of 2027. The company expects 2026 R&D expense to exceed 2025 as these programs advance.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent losses and eventual funding need
- The company remains pre-revenue and reported a $30.5 million net loss for the first six months of 2026, with an accumulated deficit of $244.7 million at June 30, 2026. It expects significant operating losses and requires additional capital before completing development.
- Clinical execution remains an early-stage risk
- OKI-345 and OKI-355 remain preclinical, with IND filings planned only for the first half of 2027. Failure to achieve safety, efficacy, manufacturing, or regulatory requirements could delay or prevent clinical development and commercialization.
- PIPE created significant dilution and resale overhang
- Risk-factor disclosure highlights substantial dilution: the 2026 PIPE issued 26,713,638 common shares plus pre-funded warrants for 9,430,957 shares, while 36,144,595 shares from that financing were registered for resale. This can pressure ownership and trading value.
What they said about what is next.
No numeric revenue or EPS guidance was provided in the 10-Q. Management expects 2026 R&D and G&A expense to be higher than 2025, plans to submit IND applications for both OKI-345 and OKI-355 in the first half of 2027, and states that cash resources are expected to fund operations into 2029.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- OnKure Therapeutics reported a net loss of $15.2 million for Q1 2026, a slight improvement from $15.9 million in Q1 2025, amidst ongoing investment in R&D with expenses down to $11.7 million from $13.0 million…
- 10-K · March 12, 2026
- OnKure is a clinical‑stage precision oncology company focused on mutation‑selective PI3Kα inhibitors, led by OKI‑219 which the filing states is ~80‑fold selective for PI3KαH1047R over wild‑type. The company has…
- 10-Q · May 6, 2025
- OnKure reported a net loss of $15.9M (net loss per share $1.19) for the quarter ended March 31, 2025, driven by higher R&D and G&A spending as it advances clinical programs. Cash and cash equivalents were $96.7M at…
- 10-Q · November 7, 2024
- OnKure’s 10-Q shows a meaningful reduction in operating burn and a narrower loss in Q3 2024 following the Merger and PIPE. Three‑month net loss improved to $(3,692) (in thousands) and EPS improved to $(1.10) versus…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OKUR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever